Diversified Trust Co Cuts Holdings in Insulet Corporation $PODD

Diversified Trust Co lowered its position in Insulet Corporation (NASDAQ:PODD) by 7.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,340 shares of the medical instruments supplier’s stock after selling 282 shares during the period. Diversified Trust Co’s holdings in Insulet were worth $1,049,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of PODD. Larson Financial Group LLC grew its holdings in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet in the 1st quarter worth approximately $26,000. SouthState Corp grew its holdings in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares during the period. Kozak & Associates Inc. acquired a new stake in shares of Insulet in the 2nd quarter worth approximately $32,000. Finally, Ramirez Asset Management Inc. acquired a new stake in shares of Insulet in the 1st quarter worth approximately $53,000.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PODD. Piper Sandler upped their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Royal Bank Of Canada increased their target price on Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Wells Fargo & Company increased their target price on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Oppenheimer increased their target price on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Finally, Canaccord Genuity Group increased their target price on Insulet from $331.00 to $353.00 and gave the company a “buy” rating in a report on Friday, August 8th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $343.06.

Insulet Trading Down 0.8%

NASDAQ:PODD opened at $330.84 on Monday. Insulet Corporation has a 12 month low of $225.37 and a 12 month high of $353.50. The firm has a market capitalization of $23.29 billion, a PE ratio of 100.56, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business’s 50-day moving average is $315.14 and its two-hundred day moving average is $294.51.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.